

Prof. Dr. Frank Tacke



Clinic Director – Medical Clinic with a focus on
hepatology and gastroenterology – Charité Berlin

Role in LiSyM-Cancer

- Project leader in DEEP-HCC
- contributes patient cohorts, samples and data

Publikationen

2023-08-01	An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH <i>Journal of Hepatology</i>
2023-07-03	Hepatic inflammatory responses in liver fibrosis. <i>Nat Rev Gastroenterol Hepatol</i>
2023-07-01	Sublethal necroptosis signaling promotes inflammation and liver cancer <i>Immunity</i>
2023-06-03	Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH) <i>Expert Opinion on Investigational Drugs</i>
2023-05-16	Cholangiokines: undervalued modulators in the hepatic microenvironment <i>Frontiers in Immunology</i>
2023-03-10	Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression <i>International Journal of Molecular Sciences</i>
2023-03-10	Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression. <i>Int J Mol Sci</i>
2023-01-01	The Multifaceted Roles of Macrophages in NAFLD Pathogenesis <i>Cellular and Molecular Gastroenterology and Hepatology</i>
2023-01-01	Therapeutic modulation of the liver immune microenvironment <i>Hepatology</i>
2023-01-01	In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations <i>Cellular and Molecular Gastroenterology and Hepatology</i>
2023-01-01	Hepatic C-X-C chemokine receptor type 6–expressing innate lymphocytes limit detrimental myeloid hyperactivation in acute liver injury <i>Hepatology Communications</i>
2023-01-01	Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression <i>Hepatology</i>
2023-01-01	The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma—State of the Art and Future Perspectives <i>Cancers</i>
2023-01-01	Hepatocytes reprogram liver macrophages involving control of TGF-β activation, influencing liver regeneration and injury <i>Hepatology Communications</i>
2022-06-23	Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD). <i>Int J Mol Sci</i>